Centogene (NASDAQ:CNTG) Coverage Initiated at BTIG Research

BTIG Research initiated coverage on shares of Centogene (NASDAQ:CNTG) in a research note published on Monday morning, Benzinga reports. The brokerage issued a buy rating and a $18.00 target price on the stock.

NASDAQ CNTG opened at $12.25 on Monday. Centogene has a 12-month low of $11.81 and a 12-month high of $15.59.

About Centogene

Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.

Read More: How to interpret Moving Average Convergence Divergence (MACD)

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.